ArticleKidney medicine2026
When Atypical Becomes Typical: A Fulminant Seronegative Anti-GBM Disease.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-glomerular basement membrane (GBM) disease is a rare autoimmune disorder characterized by circulating anti-GBM antibodies, rapidly progressive glomerulonephritis, and linear immunoglobulin G (IgG) deposition along the GBM. In contrast, atypical anti-GBM disease presents with an indolent course, absence of detectable antibodies, and variable histologic features. We report a 24-year-old male who presented with severe kidney failure (serum creatinine 17 mg/dL) and no pulmonary symptoms. Serologic tests for anti-GBM, ANCA, and ANA were negative, and complement levels were normal. Kidney biopsy revealed crescentic glomerulonephritis with 55% cellular crescents and linear polytypic IgG and C3 staining along the GBM. The patient was treated with hemodialysis, high-dose corticosteroids, cyclophosphamide, and plasma exchange according to standard anti-GBM protocols. Antibody titers remained undetectable throughout therapy. Despite aggressive treatment, kidney function did not recover, leaving the patient dialysis-dependent. This case represents an atypical manifestation of atypical anti-GBM disease, mimicking the severe phenotype of the classic form but lacking serologic confirmation. It highlights the diagnostic uncertainty and therapeutic challenges in seronegative presentations, in which antibody titers cannot guide treatment or transplantation decisions. Such cases may be more accurately described as crescentic glomerulonephritis with linear IgG staining, reflecting their overlap with classic anti-GBM disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.